246 related articles for article (PubMed ID: 30375858)
1. Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265.
White J; Dhingra SK; Deng X; El Mazouni F; Lee MCS; Afanador GA; Lawong A; Tomchick DR; Ng CL; Bath J; Rathod PK; Fidock DA; Phillips MA
ACS Infect Dis; 2019 Jan; 5(1):90-101. PubMed ID: 30375858
[TBL] [Abstract][Full Text] [Related]
2. Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance.
Mandt REK; Luth MR; Tye MA; Mazitschek R; Ottilie S; Winzeler EA; Lafuente-Monasterio MJ; Gamo FJ; Wirth DF; Lukens AK
Elife; 2023 Sep; 12():. PubMed ID: 37737220
[TBL] [Abstract][Full Text] [Related]
3. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.
Llanos-Cuentas A; Casapia M; Chuquiyauri R; Hinojosa JC; Kerr N; Rosario M; Toovey S; Arch RH; Phillips MA; Rozenberg FD; Bath J; Ng CL; Cowell AN; Winzeler EA; Fidock DA; Baker M; Möhrle JJ; Hooft van Huijsduijnen R; Gobeau N; Araeipour N; Andenmatten N; Rückle T; Duparc S
Lancet Infect Dis; 2018 Aug; 18(8):874-883. PubMed ID: 29909069
[TBL] [Abstract][Full Text] [Related]
4. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.
Phillips MA; Lotharius J; Marsh K; White J; Dayan A; White KL; Njoroge JW; El Mazouni F; Lao Y; Kokkonda S; Tomchick DR; Deng X; Laird T; Bhatia SN; March S; Ng CL; Fidock DA; Wittlin S; Lafuente-Monasterio M; Benito FJ; Alonso LM; Martinez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Haselden JN; Louttit J; Cui Y; Sridhar A; Zeeman AM; Kocken C; Sauerwein R; Dechering K; Avery VM; Duffy S; Delves M; Sinden R; Ruecker A; Wickham KS; Rochford R; Gahagen J; Iyer L; Riccio E; Mirsalis J; Bathhurst I; Rueckle T; Ding X; Campo B; Leroy D; Rogers MJ; Rathod PK; Burrows JN; Charman SA
Sci Transl Med; 2015 Jul; 7(296):296ra111. PubMed ID: 26180101
[TBL] [Abstract][Full Text] [Related]
5. In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model.
Mandt REK; Lafuente-Monasterio MJ; Sakata-Kato T; Luth MR; Segura D; Pablos-Tanarro A; Viera S; Magan N; Ottilie S; Winzeler EA; Lukens AK; Gamo FJ; Wirth DF
Sci Transl Med; 2019 Dec; 11(521):. PubMed ID: 31801884
[TBL] [Abstract][Full Text] [Related]
6. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.
Phillips MA; White KL; Kokkonda S; Deng X; White J; El Mazouni F; Marsh K; Tomchick DR; Manjalanagara K; Rudra KR; Wirjanata G; Noviyanti R; Price RN; Marfurt J; Shackleford DM; Chiu FC; Campbell M; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Martinez MS; Lafuente-Monasterio M; Kaminsky W; Silue K; Zeeman AM; Kocken C; Leroy D; Blasco B; Rossignol E; Rueckle T; Matthews D; Burrows JN; Waterson D; Palmer MJ; Rathod PK; Charman SA
ACS Infect Dis; 2016 Dec; 2(12):945-957. PubMed ID: 27641613
[TBL] [Abstract][Full Text] [Related]
7. In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth.
Ross LS; Gamo FJ; Lafuente-Monasterio MJ; Singh OM; Rowland P; Wiegand RC; Wirth DF
J Biol Chem; 2014 Jun; 289(26):17980-95. PubMed ID: 24782313
[TBL] [Abstract][Full Text] [Related]
8. Identification of 3,4-Dihydro-2
Hartuti ED; Sakura T; Tagod MSO; Yoshida E; Wang X; Mochizuki K; Acharjee R; Matsuo Y; Tokumasu F; Mori M; Waluyo D; Shiomi K; Nozaki T; Hamano S; Shiba T; Kita K; Inaoka DK
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281290
[No Abstract] [Full Text] [Related]
9. Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.
Kokkonda S; Deng X; White KL; Coteron JM; Marco M; de Las Heras L; White J; El Mazouni F; Tomchick DR; Manjalanagara K; Rudra KR; Chen G; Morizzi J; Ryan E; Kaminsky W; Leroy D; Martínez-Martínez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Waterson D; Burrows JN; Matthews D; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2016 Jun; 59(11):5416-31. PubMed ID: 27127993
[TBL] [Abstract][Full Text] [Related]
10. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds.
Deng X; Gujjar R; El Mazouni F; Kaminsky W; Malmquist NA; Goldsmith EJ; Rathod PK; Phillips MA
J Biol Chem; 2009 Sep; 284(39):26999-7009. PubMed ID: 19640844
[TBL] [Abstract][Full Text] [Related]
11. DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with
Collins KA; Rückle T; Elliott S; Marquart L; Ballard E; Chalon S; Griffin P; Möhrle JJ; McCarthy JS
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30858218
[TBL] [Abstract][Full Text] [Related]
12. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors.
Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS
Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381
[TBL] [Abstract][Full Text] [Related]
13. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.
Coteron JM; Marco M; Esquivias J; Deng X; White KL; White J; Koltun M; El Mazouni F; Kokkonda S; Katneni K; Bhamidipati R; Shackleford DM; Angulo-Barturen I; Ferrer SB; Jiménez-Díaz MB; Gamo FJ; Goldsmith EJ; Charman WN; Bathurst I; Floyd D; Matthews D; Burrows JN; Rathod PK; Charman SA; Phillips MA
J Med Chem; 2011 Aug; 54(15):5540-61. PubMed ID: 21696174
[TBL] [Abstract][Full Text] [Related]
14. Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.
Kokkonda S; Deng X; White KL; El Mazouni F; White J; Shackleford DM; Katneni K; Chiu FCK; Barker H; McLaren J; Crighton E; Chen G; Angulo-Barturen I; Jimenez-Diaz MB; Ferrer S; Huertas-Valentin L; Martinez-Martinez MS; Lafuente-Monasterio MJ; Chittimalla R; Shahi SP; Wittlin S; Waterson D; Burrows JN; Matthews D; Tomchick D; Rathod PK; Palmer MJ; Charman SA; Phillips MA
J Med Chem; 2020 May; 63(9):4929-4956. PubMed ID: 32248693
[TBL] [Abstract][Full Text] [Related]
15. DSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria.
Bélard S; Ramharter M
Lancet Infect Dis; 2018 Aug; 18(8):819-820. PubMed ID: 29909070
[No Abstract] [Full Text] [Related]
16. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
McCarthy JS; Lotharius J; Rückle T; Chalon S; Phillips MA; Elliott S; Sekuloski S; Griffin P; Ng CL; Fidock DA; Marquart L; Williams NS; Gobeau N; Bebrevska L; Rosario M; Marsh K; Möhrle JJ
Lancet Infect Dis; 2017 Jun; 17(6):626-635. PubMed ID: 28363636
[TBL] [Abstract][Full Text] [Related]
17. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.
Sulyok M; Rückle T; Roth A; Mürbeth RE; Chalon S; Kerr N; Samec SS; Gobeau N; Calle CL; Ibáñez J; Sulyok Z; Held J; Gebru T; Granados P; Brückner S; Nguetse C; Mengue J; Lalremruata A; Sim BKL; Hoffman SL; Möhrle JJ; Kremsner PG; Mordmüller B
Lancet Infect Dis; 2017 Jun; 17(6):636-644. PubMed ID: 28363637
[TBL] [Abstract][Full Text] [Related]
18. Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance.
Lukens AK; Ross LS; Heidebrecht R; Javier Gamo F; Lafuente-Monasterio MJ; Booker ML; Hartl DL; Wiegand RC; Wirth DF
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):799-804. PubMed ID: 24381157
[TBL] [Abstract][Full Text] [Related]
19. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria.
Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N
Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917
[TBL] [Abstract][Full Text] [Related]
20. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.
Phillips MA; Gujjar R; Malmquist NA; White J; El Mazouni F; Baldwin J; Rathod PK
J Med Chem; 2008 Jun; 51(12):3649-53. PubMed ID: 18522386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
